Peter Attia· MD
what about genetic diseases of the eye that's also a place that's easy to reach and you don't require systemic Administration
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
what about genetic diseases of the eye that's also a place that's easy to reach and you don't require systemic Administration
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the way that these diseases in the eye are treated is by designing uh cast n and a guide RNA to be able to uh sort of knock out the gene that is causing uh degenerative conditions in the eye and then using a viral Vector to deliver the castai gene uh and also the guide RNA intraocularly